ODT - Odonate Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.10
+0.97 (+3.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close32.13
Open32.43
Bid9.84 x 800
Ask0.00 x 3100
Day's Range31.44 - 33.84
52 Week Range11.54 - 43.75
Volume98,467
Avg. Volume105,431
Market Cap1.062B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.31
Earnings DateNov 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.50
  • Business Wire

    Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019

    Odonate Therapeutics, Inc. , a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2019.

  • Hedge Funds Have Never Been This Bullish On Odonate Therapeutics, Inc. (ODT)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Odonate Therapeutics, Inc. (ODT)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Business Wire

    Odonate Therapeutics Announces Completion of Enrollment in CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer. The Company expects to report top-line results from CONTESSA in the third quarter of 2020. Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer.

  • Odonate Therapeutics Enters Oversold Territory
    Zacks

    Odonate Therapeutics Enters Oversold Territory

    Odonate Therapeutics, Inc. (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • 4 of the Best Stocks With Solid Earnings Acceleration
    Zacks

    4 of the Best Stocks With Solid Earnings Acceleration

    Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.

  • Here's Why Odonate Therapeutics Stock Jumped 70.7% in June
    Motley Fool

    Here's Why Odonate Therapeutics Stock Jumped 70.7% in June

    Purchases disclosed by a company insider boosted investor confidence and the company's chemotherapy pill.

  • GuruFocus.com

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Odonate Therapeutics, Carnival PLC, TG Therapeutics, Liberty Latin America and Biohaven

  • GuruFocus.com

    Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $20 million of Shares

    CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 769,231 shares of ODT on 06/26/2019 at an average price of $26 a share.

  • Business Wire

    Odonate Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock, offered at a price of $26.00 per share. In addition, Odonate has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock on the same terms and conditions. All shares of common stock sold in the offering are being sold by Odonate.

  • Business Wire

    Odonate Therapeutics Announces Public Offering of Shares of Common Stock

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has commenced an underwritten public offering of approximately $100 million of shares of its common stock. In addition, Odonate has granted the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock. All of the shares of common stock to be sold in the underwritten public offering are being offered by Odonate.

  • GuruFocus.com

    Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $1.3 million of Shares

    CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 50,000 shares of ODT on 06/18/2019 at an average price of $26.15 a share.

  • GuruFocus.com

    Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $2.1 million of Shares

    CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 76,308 shares of ODT on 06/07/2019 at an average price of $27.36 a share.

  • Business Wire

    Independent Data Monitoring Committee (IDMC) Recommends CONTESSA Continue with No Modifications following Planned Interim Efficacy Futility Analysis

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that the IDMC for CONTESSA, Odonate’s Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer, recommended that the study continue with no modifications following a planned interim efficacy futility analysis. The interim efficacy futility analysis was based on a pre-specified analysis of the first approximate 100 progression-free survival (PFS) events that occurred in the study. PFS is the primary endpoint of CONTESSA.

  • Business Wire

    Odonate Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019, at 2:00 p.m. Eastern Time. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer.

  • Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
    Zacks

    Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

    Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

  • Small Drug Stocks Outlook: Near-Term Prospects Encouraging
    Zacks

    Small Drug Stocks Outlook: Near-Term Prospects Encouraging

    Small Drug Stocks Outlook: Near-Term Prospects Encouraging

  • Business Wire

    Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019

    Odonate Therapeutics, Inc. , a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2019.

  • Business Wire

    Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today presented results of preclinical studies of tesetaxel, Odonate’s investigational, orally administered taxane, at the American Association for Cancer Research (AACR) Annual Meeting 2019. These preclinical results indicate that, following oral administration, tesetaxel achieves brain concentrations that exceed concentrations required for tumor killing for a sustained period of time. “The development of effective treatment options for patients with brain metastases remains an enormous unmet medical need”, said Nancy Lin, M.D., Associate Chief of Breast Oncology, Susan F. Smith Center for Women’s Cancers, and Director of the EMBRACE Metastatic Breast Cancer Program, Dana-Farber Cancer Institute.

  • Business Wire

    Odonate Therapeutics Initiates CONTESSA TRIO

    Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of CONTESSA TRIO, a multi-cohort, multicenter, Phase 2 study of tesetaxel, Odonate’s investigational, orally administered taxane. Nivolumab and pembrolizumab (PD-1 inhibitors) and atezolizumab (a PD-L1 inhibitor) are IO agents approved for the treatment of multiple types of cancer.

  • Have Insiders Been Buying Odonate Therapeutics, Inc. (NASDAQ:ODT) Shares?
    Simply Wall St.

    Have Insiders Been Buying Odonate Therapeutics, Inc. (NASDAQ:ODT) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mentionRead More...